Quote:

---

I wonder if the down-regulation of VEGF, from Leronlimab, can be measured against what bevacizumab does?

---

Quote:

---

Incidence rates of grade ≥3 hypertension, proteinuria, bleeding, wound-healing complications, gastrointestinal perforations, and thromboembolic events were increased with bevacizumab treatment.

---

Looking at the type of serious adverse events (most hematological related) it looks like bevacizumab shuts down VEGF too much. Leronlimab downregulates it to a very good extent but not completely which allows it's necessary functioning.